Patents by Inventor Lawrence C. Kuo

Lawrence C. Kuo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SUBSTITUTED 3-DIALKYLAMINOMETHYL-PIPERIDIN-4-YL-BENZAMIDES AND METHODS OF MAKING AND USING SAME
    Publication number: 20240043387
    Abstract: The invention relates to certain substituted 3-dialkylaminomethyl-piperidin-4-yl-benzamides, and compositions comprising the same, which in certain embodiments are useful for treating and/or preventing pain in a subject in need thereof.
    Type: Application
    Filed: October 31, 2022
    Publication date: February 8, 2024
    Inventors: Brett A. Tounge, Shariff Bayoumy, Lawrence C. Kuo, Scott L. Dax
  • Substituted Ureas and Methods of Making and Using Same
    Publication number: 20220315567
    Abstract: The invention relates to substituted ureas, and compositions comprising the same, which in certain embodiments are useful for treating and/or preventing pain in a subject in need thereof.
    Type: Application
    Filed: November 5, 2021
    Publication date: October 6, 2022
    Inventors: Brett A. Tounge, Shariff Bayoumy, Lawrence C. Kuo, Scott Dax
  • Substituted 3-dialkylaminomethyl-piperidin-4-yl-benzamides and methods of making and using same
    Patent number: 11319290
    Abstract: The invention relates to certain substituted 3-dialkylaminomethyl-piperidin-4-yl-benzamides, and compositions comprising the same, which in certain embodiments are useful for treating and/or preventing pain in a subject in need thereof.
    Type: Grant
    Filed: September 18, 2020
    Date of Patent: May 3, 2022
    Assignee: Mebias Discovery, Inc.
    Inventors: Brett A. Tounge, Shariff Bayoumy, Lawrence C. Kuo, Scott L. Dax
  • Substituted ureas and methods of making and using same
    Patent number: 11198685
    Abstract: The invention relates to substituted ureas, and compositions comprising the same, which in certain embodiments are useful for treating and/or preventing pain in a subject in need thereof.
    Type: Grant
    Filed: May 18, 2020
    Date of Patent: December 14, 2021
    Assignee: Mebias Discovery, Inc.
    Inventors: Brett A. Tounge, Shariff Bayoumy, Lawrence C. Kuo, Scott Dax
  • Substituted 3-Dialkylaminomethyl-Piperidin-4-yl-Benzamides and Methods of Making and Using Same
    Publication number: 20210101868
    Abstract: The invention relates to certain substituted 3-dialkylaminomethyl-piperidin-4-yl-benzamides, and compositions comprising the same, which in certain embodiments are useful for treating and/or preventing pain in a subject in need thereof.
    Type: Application
    Filed: September 18, 2020
    Publication date: April 8, 2021
    Inventors: Brett A. Tounge, Shariff Bayoumy, Lawrence C. Kuo, Scott L. Dax
  • Substituted 3-dialkylaminomethyl-piperidin-4-yl-benzamides and methods of making and using same
    Patent number: 10836728
    Abstract: The invention relates to certain substituted 3-dialkylaminomethyl-piperidin-4-yl-benzamides, and compositions comprising the same, which in certain embodiments are useful for treating and/or preventing pain in a subject in need thereof.
    Type: Grant
    Filed: January 17, 2018
    Date of Patent: November 17, 2020
    Assignee: Mebias Discovery, Inc.
    Inventors: Brett A. Tounge, Shariff Bayoumy, Lawrence C. Kuo, Scott L. Dax
  • Substituted Ureas and Methods of Making and Using Same
    Publication number: 20200308155
    Abstract: The invention relates to substituted ureas, and compositions comprising the same, which in certain embodiments are useful for treating and/or preventing pain in a subject in need thereof.
    Type: Application
    Filed: May 18, 2020
    Publication date: October 1, 2020
    Inventors: Brett A. Tounge, Shariff Bayoumy, Lawrence C. Kuo, Scott Dax
  • Substituted ureas and methods of making and using same
    Patent number: 10683283
    Abstract: The invention relates to substituted ureas, and compositions comprising the same, which in certain embodiments are useful for treating and/or preventing pain in a subject in need thereof.
    Type: Grant
    Filed: August 31, 2017
    Date of Patent: June 16, 2020
    Assignee: MEBIAS DISCOVERY, INC.
    Inventors: Brett A. Tounge, Shariff Bayoumy, Lawrence C. Kuo, Scott Dax
  • SUBSTITUTED 3-DIALKYLAMINOMETHYL-PIPERIDIN-4-YL-BENZAMIDES AND METHODS OF MAKING AND USING SAME
    Publication number: 20190337901
    Abstract: The invention relates to certain substituted 3-dialkylaminomethyl-piperidin-4-yl-benzamides, and compositions comprising the same, which in certain embodiments are useful for treating and/or preventing pain in a subject in need thereof.
    Type: Application
    Filed: January 17, 2018
    Publication date: November 7, 2019
    Inventors: BRETT A. TOUNGE, SHARIFF BAYOUMY, LAWRENCE C. KUO, SCOTT L. DAX
  • SUBSTITUTED UREAS AND METHODS OF MAKING AND USING SAME
    Publication number: 20190194178
    Abstract: The invention relates to substituted ureas, and compositions comprising the same, which in certain embodiments are useful for treating and/or preventing pain in a subject in need thereof.
    Type: Application
    Filed: August 31, 2017
    Publication date: June 27, 2019
    Inventors: BRETT A. TOUNGE, SHARIFF BAYOUMY, LAWRENCE C. KUO, SCOTT DAX
  • Indazole compounds useful as ketohexokinase inhibitors
    Patent number: 9771375
    Abstract: The present invention is directed to substituted indazole compounds, pharmaceutical compositions of these compounds and methods of use thereof. The compounds of the present invention are ketohexokinase (KHK) inhibitors, useful for treating or ameliorating a KHK mediated metabolic disorders and/or diseases such as obesity, Type II diabetes mellitus and Metabolic Syndrome X. In some embodiments, the substituted indazole compounds are of formula I, wherein R1-R3, Q, X, Y, Z, a, and b are defined herein.
    Type: Grant
    Filed: July 23, 2014
    Date of Patent: September 26, 2017
    Assignee: Janssen Pharmaceutica NV
    Inventors: Xuqing Zhang, Marta C Abad, Alan C. Gibbs, Gee-Hong Kuo, Fengbin Song, Zhihua Sui, Lawrence C. Kuo
  • Methods of treatment using allosteric processing inhibitors for matrix metalloproteinases
    Patent number: 8883473
    Abstract: The present invention includes a crystal comprising a complex of the pro form of a matrix metalloprotease (proMMP) and a small-molecule allosteric processing inhibitor that inhibits that activation of the proMMP, methods for identifying small-molecule allosteric processing inhibitors that inhibit the activation of a proMMP, and methods of treatment using small-molecule allosteric processing inhibitors that inhibit the activation of a proMMP. The present invention relates to the crystal structure of a complex of proMMP9 bound to a small-molecule allosteric processing inhibitor that inhibits activation of proMMP9. The invention further relates to the use of the methods and the crystal and related structural information for designing, selecting and/or optimizing small-molecule allosteric processing inhibitors that inhibit activation of proMMP9 and proMMP9 homologues.
    Type: Grant
    Filed: June 26, 2012
    Date of Patent: November 11, 2014
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Kristi A. Leonard, Richard Scott Alexander, Joseph Kent Barbay, Roger F. Bone, Carl Crysler, Ingrid Christa Deckman, Paul F. Jackson, Lawrence C. Kuo, Frank A. Lewandowski, Diane M. Maguire, Carl Manthey, Cynthia M. Milligan, Beverley Moore, Kenneth J. Rhodes, Robert H. Scannevin, Celine Schalk-Hihi, Barry Springer, John C. Spurlino, Matthew J. Todd, Brett A. Tounge, Aihua Wang
  • Indazole compounds useful as ketohexokinase inhibitors
    Patent number: 8822447
    Abstract: The present invention is directed to substituted indazole compounds of formula (I) pharmaceutical compositions of these compounds and methods of use thereof. The compounds of the present invention are ketohexokinase (KHK) inhibitors, useful for treating or ameliorating a KHK mediated metabolic disorders and/or diseases such as obesity, Type II diabetes mellitus and Metabolic Syndrome X.
    Type: Grant
    Filed: April 21, 2011
    Date of Patent: September 2, 2014
    Assignee: Janssen Pharmaceutica NV
    Inventors: Xuqing Zhang, Marta C. Abad, Alan C. Gibbs, Gee-Hong Kuo, Lawrence C. Kuo, Fengbin Song, Zhihua Sui
  • Methods for designing, selecting and/or optimizing allosteric processing inhibitors for matrix metalloproteinases
    Patent number: 8798939
    Abstract: The present invention includes a crystal comprising a complex of the pro form of a matrix metalloprotease (proMMP) and a small-molecule allosteric processing inhibitor that inhibits that activation of the proMMP, methods for identifying small-molecule allosteric processing inhibitors that inhibit the activation of a proMMP, and methods of treatment using small-molecule allosteric processing inhibitors that inhibit the activation of a proMMP. The present invention relates to the crystal structure of a complex of proMMP9 bound to a small-molecule allosteric processing inhibitor that inhibits activation of proMMP9. The invention further relates to the use of the methods and the crystal and related structural information for designing, selecting and/or optimizing small-molecule allosteric processing inhibitors that inhibit activation of proMMP9 and proMMP9 homologues.
    Type: Grant
    Filed: June 26, 2012
    Date of Patent: August 5, 2014
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Kristi A. Leonard, Richard Scott Alexander, Joseph Kent Barbay, Roger F. Bone, Ingrid Christa Deckman, Paul F. Jackson, Lawrence C. Kuo, Frank A. Lewandowski, Diane M. Maguire, Cynthia M. Milligan, Kenneth J. Rhodes, Robert H. Scannevin, Celine Schalk-Hihi, Barry Springer, John C. Spurlino, Matthew J. Todd, Brett A. Tounge, Aihua Wang
  • Crystal structure of the pro form of a matrix metalloproteinase and an allosteric processing inhibitor
    Patent number: 8753857
    Abstract: The present invention includes a crystal comprising a complex of the pro form of a matrix metalloprotease (proMMP) and a small-molecule allosteric processing inhibitor that inhibits that activation of the proMMP, methods for identifying small-molecule allosteric processing inhibitors that inhibit the activation of a proMMP, and methods of treatment using small-molecule allosteric processing inhibitors that inhibit the activation of a proMMP. The present invention relates to the crystal structure of a complex of proMMP9 bound to a small-molecule allosteric processing inhibitor that inhibits activation of proMMP9. The invention further relates to the use of the methods and the crystal and related structural information for designing, selecting and/or optimizing small-molecule allosteric processing inhibitors that inhibit activation of proMMP9 and proMMP9 homologues.
    Type: Grant
    Filed: June 26, 2012
    Date of Patent: June 17, 2014
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Kristi A. Leonard, Richard Scott Alexander, Joseph Kent Barbay, Roger F. Bone, Ingrid Christa Deckman, Paul F. Jackson, Lawrence C. Kuo, Frank A. Lewandowski, Diane M. Maguire, Cynthia M. Milligan, Kenneth J. Rhodes, Robert H. Scannevin, Celine Schalk-Hihi, Barry Springer, John C. Spurlino, Matthew J. Todd, Brett A. Tounge, Aihua Wang
  • Crystal Structure of the Pro Form of a Matrix Metalloproteinase and an Allosteric Processing Inhibitor
    Publication number: 20130166268
    Abstract: The present invention includes a crystal comprising a complex of the pro form of a matrix metalloprotease (proMMP) and a small-molecule allosteric processing inhibitor that inhibits that activation of the proMMP, methods for identifying small-molecule allosteric processing inhibitors that inhibit the activation of a proMMP, and methods of treatment using small-molecule allosteric processing inhibitors that inhibit the activation of a proMMP. The present invention relates to the crystal structure of a complex of proMMP9 bound to a small-molecule allosteric processing inhibitor that inhibits activation of proMMP9. The invention further relates to the use of the methods and the crystal and related structural information for designing, selecting and/or optimizing small-molecule allosteric processing inhibitors that inhibit activation of proMMP9 and proMMP9 homologues.
    Type: Application
    Filed: June 26, 2012
    Publication date: June 27, 2013
    Inventors: Kristi A. Leonard, Richard Scott Alexander, Joseph Kent Barbay, Roger F. Bone, Ingrid Christa Deckman, Paul F. Jackson, Lawrence C. Kuo, Frank A. Lewandowski, Diane M. Maguire, Cynthia M. Milligan, Kenneth J. Rhodes, Robert H. Scannevin, Celine Schalk-Hihi, Barry Springer, John C. Spurlino, Matthew J. Todd, Brett Andrew Tongue, Aihua Wang
  • Methods of Treatment Using Allosteric Processing Inhibitors for Matrix Metalloproteinases
    Publication number: 20130040994
    Abstract: The present invention includes a crystal comprising a complex of the pro form of a matrix metalloprotease (proMMP) and a small-molecule allosteric processing inhibitor that inhibits that activation of the proMMP, methods for identifying small-molecule allosteric processing inhibitors that inhibit the activation of a proMMP, and methods of treatment using small-molecule allosteric processing inhibitors that inhibit the activation of a proMMP. The present invention relates to the crystal structure of a complex of proMMP9 bound to a small-molecule allosteric processing inhibitor that inhibits activation of proMMP9. The invention further relates to the use of the methods and the crystal and related structural information for designing, selecting and/or optimizing small-molecule allosteric processing inhibitors that inhibit activation of proMMP9 and proMMP9 homologues.
    Type: Application
    Filed: June 26, 2012
    Publication date: February 14, 2013
    Inventors: Kristi A. Leonard, Richard Scott Alexander, Joseph Kent Barbay, Roger F. Bone, Carl Crysler, Ingrid Christa Deckman, Paul F. Jackson, Lawrence C. Kuo, Frank A. Lewandowski, Diane M. Maguire, Carl Manthey, Cynthia M. Milligan, Beverley Moore, Kenneth J. Rhodes, Robert H. Scannevin, Celine Schalk-Hihi, Barry Springer, John C. Spurlino, Matthew J. Todd, Brett Andrew Tongue, Aihua Wang
  • Crystal Structure of the Pro Form of a Matrix Metalloproteinase and an Allosteric Processing Inhibitor
    Publication number: 20130040360
    Abstract: The present invention includes a crystal comprising a complex of the pro form of a matrix metalloprotease (proMMP) and a small-molecule allosteric processing inhibitor that inhibits that activation of the proMMP, methods for identifying small-molecule allosteric processing inhibitors that inhibit the activation of a proMMP, and methods of treatment using small-molecule allosteric processing inhibitors that inhibit the activation of a proMMP. The present invention relates to the crystal structure of a complex of proMMP9 bound to a small-molecule allosteric processing inhibitor that inhibits activation of proMMP9. The invention further relates to the use of the methods and the crystal and related structural information for designing, selecting and/or optimizing small-molecule allosteric processing inhibitors that inhibit activation of proMMP9 and proMMP9 homologues.
    Type: Application
    Filed: June 26, 2012
    Publication date: February 14, 2013
    Inventors: Kristi A. Leonard, Richard Scott Alexander, Joseph Kent Barbay, Roger F. Bone, Ingrid Christa Deckman, Paul F. Jackson, Lawrence C. Kuo, Frank A. Lewandowski, Diane M. Maguire, Cynthia M. Milligan, Kenneth J. Rhodes, Robert H. Scannevin, Celine Schalk-Hihi, Barry Springer, John C. Spurlino, Matthew J. Todd, Brett Andrew Tongue, Aihua Wang
  • INDAZOLE COMPOUNDS USEFUL AS KETOHEXOKINASE INHIBITORS
    Publication number: 20110263559
    Abstract: The present invention is directed to substituted indazole compounds, pharmaceutical compositions of these compounds and methods of use thereof. The compounds of the present invention are ketohexokinase (KHK) inhibitors, useful for treating or ameliorating a KHK mediated metabolic disorders and/or diseases such as obesity, Type II diabetes mellitus and Metabolic Syndrome X.
    Type: Application
    Filed: April 21, 2011
    Publication date: October 27, 2011
    Inventors: Xuqing ZHANG, Marta G. ABAD, Alan C. GIBBS, Gee-Hong KUO, Lawrence C. KUO, Fengbin SONG, Zhihua SUI
  • Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
    Publication number: 20040110717
    Abstract: The present invention provides nucleoside derivatives which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B polymerase, as inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such nucleoside derivatives alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside derivatives of the present invention.
    Type: Application
    Filed: January 16, 2004
    Publication date: June 10, 2004
    Inventors: Steven S. Carroll, Robert L. LaFemina, Dawn L. Hall, Amy L. Himmelberger, Lawrence C. Kuo, David B. Olsen, Carrie A. Rutkowski, Joanne E. Tomassini, Malcolm MacCoss, Haoyun An, Balkrishen Bhat, Neelima Bhat, Phillip Dan Cook, Anne B. Eldrup, Thazha P. Prakash, Marija Prhavc, Charles J. Guinosso